Aquestive Therapeutics Faces Securities Fraud Lawsuit Despite Anaphylm FDA Review Progress

Key Takeaways

• Aquestive Therapeutics faces securities fraud class action lawsuit despite FDA accepting Anaphylm NDA with January 31, 2026 PDUFA date
• Lawsuit alleges pattern of overly optimistic messaging to investors about FDA review process and regulatory prospects
• Anaphylm sublingual film represents potential alternative to traditional epinephrine auto-injectors for anaphylaxis treatment

---

NEW YORK - Aquestive Therapeutics, Inc. (NASDAQ: AQST) is facing a securities fraud class action lawsuit announced April 30, 2026, despite having an FDA-accepted New Drug Application (NDA) for its Anaphylm sublingual film with a January 31, 2026 PDUFA goal date.

Legal Allegations Against Management

The lawsuit, announced by SueWallSt, alleges that Aquestive management engaged in a pattern of misleading communications with investors regarding the FDA review process for Anaphylm. According to the complaint, company executives made overly optimistic statements about regulatory timelines and prospects.

Specific allegations include management telling investors that the FDA confirmed it was “aiming for an on-time review” and that no Advisory Committee meeting would be required. The lawsuit suggests these communications created unrealistic expectations among shareholders.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for emergency medicine/allergy, with Anaphylm most exposed to upcoming decisions. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Anaphylm’s Regulatory Status

Despite the legal challenges, Anaphylm’s regulatory pathway continues to progress. The FDA’s acceptance of the NDA and assignment of a January 2026 PDUFA date indicates the agency is conducting a standard review of the sublingual film formulation.

Anaphylm is designed as an alternative delivery method for emergency anaphylaxis treatment, potentially offering advantages over traditional epinephrine auto-injectors like EpiPen and Auvi-Q. The sublingual film format could provide faster absorption and easier administration in emergency situations.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Impact and Investor Concerns

The securities fraud allegations raise significant concerns about management credibility and corporate governance at Aquestive Therapeutics. Investors who suffered losses are being encouraged to participate in the class action lawsuit, which could result in substantial financial exposure for the company.

The timing of the lawsuit, coming months before the PDUFA date, creates additional uncertainty for shareholders and potential commercial partners. Even if Anaphylm receives FDA approval, the legal overhang could impact the company’s ability to effectively commercialize the product.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for emergency medicine/allergy pricing, access, and launch sequencing.

Competitive Landscape

The anaphylaxis treatment market is dominated by established epinephrine auto-injectors, but there remains opportunity for innovative delivery methods. Anaphylm’s sublingual film approach could differentiate it from existing options if clinical data supports superior pharmacokinetics or patient convenience.

However, the current legal challenges may hamper Aquestive’s ability to compete effectively against well-established competitors with significant market presence and resources.

IntelligenceStrategic Takeaways▾

Aquestive Therapeutics faces securities fraud class action lawsuit despite FDA accepting Anaphylm NDA with January 31, 2026 PDUFA date Lawsuit alleges pattern of overly optimistic messaging to investors about FDA review process and regulatory prospects Anaphylm sublingual film represents potential alternative to traditional epinephrine auto-injectors for anaphylaxis treatment

Looking Ahead

The January 2026 PDUFA date remains a critical milestone for Aquestive Therapeutics, but the securities fraud lawsuit adds a layer of complexity to the company’s prospects. Investors will be closely monitoring both the FDA’s regulatory decision and the progression of the legal proceedings.

The case highlights the importance of accurate and balanced communications with investors, particularly for biotech companies navigating complex regulatory processes where outcomes remain uncertain until final agency decisions.

---

Frequently Asked Questions

What does this lawsuit mean for Anaphylm’s FDA approval prospects?

The securities fraud lawsuit does not directly impact Anaphylm’s regulatory review, which continues on track for the January 31, 2026 PDUFA date. However, it raises concerns about management credibility and could affect commercialization efforts if approved.

When will Anaphylm be available to patients?

Anaphylm’s availability depends on FDA approval, with a decision expected by the January 31, 2026 PDUFA goal date. If approved, commercial launch timing would depend on manufacturing readiness and market access negotiations.

How does Anaphylm compare to existing anaphylaxis treatments?

Anaphylm is a sublingual film designed to offer an alternative to traditional epinephrine auto-injectors like EpiPen. The film format potentially provides faster absorption and easier administration, though clinical data will determine its comparative effectiveness.

Related coverage

• Nektar Therapeutics pipeline update: REZPEG, amphotericin B and UK site changes
• Vanda tradipitant update: FDA re-review extends to Dec. 5, 2025